Dr. Lindsay Rosenwald, performs projects with that assembly of organizations which is mostly involving investment money managing, asset control, plus direct investing and venture capital in the life-science and biotechnological business. He uses a mixture of U.S. based and also foreign hedge funds along with private equity for the purpose of managing their investor assets. He is a broker dealer who has FINRA membership and has specialized in helping public and private biotechnology organizations in the initial stage in supervising private and public placement offerings. His organization is a highly focused group whose effort is to take a comprehensive profit in both private and public companies. This includes troubled turn-around and start-up businesses. It is both a health care investment bank and an worldwide run pharmaceutical item improvement firm. Supplementary to that Dr. Lindsay Rosenwald has a membership with the Managing Member of Orion Biomedical Fund, LP and the Orion Biomedical Offshore Fund, LP. Both of these organizations are managing in Financing. For more than 20 years, Dr. Lindsay Rosenwald has collaborated as a Wall Street capitalist in biotechnology. He has originated and re-capitalized many private and public life-sciences and biotechnology establishments. The businesses has so far invented three different chemical compounds that have been accepted by the FDA and they presently have a considerable number of products that are even still undergoing clinical trials. One of these is a portfolio company known as PolaRx BioPharmaceuticals, Inc., has been granted a final marketing approval for a leukemia compound recognized as arsenic trioxide. This was concluded only 30 months, an industry record, after the treatment of the very first testees was processed in a corporate clinical trial. 5 Other than Cougar Biotechnology, Dr. Lindsay Rosenwald has in addition taken it upon himself to also support or create such companies as Bradley Pharmaceuticals, Inc., Repligen Corporation, Avigen, Inc., Cardiome Pharma Corp., Neose Technologies Inc., Biocryst Pharmaceuticals, Inc, Cypress Bioscience, Inc., Genta, Inc, Discovery Laboratories, Inc., Indevus Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Cell Therapeutics, Inc., and Hudson Health Sciences, Inc. As far as his educational history, Dr. Lindsay Rosenwald was a graduate of Abington High School, in the southeast vicinity of Pennsylvania, back in 1973. He then went on to graduate Beta Gamma Sigma as well as a degree in Finance and Economy from Pennsylvania State University in 1977. Shortly after, he attained employment as a management consultant (working independently), performing for various health care establishments during the years 1977 to 1979 and then entering himself into the Temple University School of Medicine. He graduated from Temple in 1983 and soon afterward was awarded an internship at the Abington Medical Hospital, continuing in the private health system until the year 1986. Dr. Lindsay Rosenwald then moved on to Wall Street in order to syndicate his financial and medical skills and function as a doctor/financial analyst.
Dr. Lindsay Rosenwald reputed himself as a corporate finance managing director for D.H. Blair & Company, in the year of 1988. This was a privately owned investment based business. There, he was the leader of a team of three physician-financiers that sought through the medical community for any new and profitable break-through that could make use of private investment. They located various schools of medicine, universities, hospitals, drug companies, study groups, and scientific firms. He has worked within the biotechnology and bioresearch disciplines. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires with a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He quit in order to contribute additional time performing in the biotechnology market. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another business that was first founded by Dr. Rosenwald and was originated completely on abiraterone acetate. Abiraterone Acetate, even though it had not yet attained phase III in clinical testing trials, was showing so much potential in the therapy and management for prostate cancer that Johnson & Johnson offered a short-term unification bid and procurement for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the scores of ventures which have imparted financing and resources to portfolio companies, has also began the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in offering millions of dollars in aid of many medical and scientific instruction institutions.